Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

PHAR

Pharming Group NV (PHAR)

Pharming Group NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PHAR
DatumZeitQuelleÜberschriftSymbolFirma
30/05/202423h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
21/05/202419h54Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
15/05/202417h52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
08/05/202412h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
08/01/202415h17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
26/10/202315h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
24/08/202308h00PR Newswire (US)Pharming Group to participate in September investor conferencesNASDAQ:PHARPharming Group NV
14/08/202307h00PR Newswire (US)Pharming Group to convene Extraordinary General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
09/08/202307h00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
09/08/202307h00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
03/08/202317h09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
03/08/202307h00PR Newswire (US)Pharming Group reports second quarter and first half 2023 financial resultsNASDAQ:PHARPharming Group NV
18/07/202307h00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
18/07/202307h00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
13/07/202308h00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
13/07/202308h00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
01/06/202312h15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
01/06/202307h00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
01/06/202307h00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
25/05/202308h00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
25/05/202308h00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
17/05/202317h28PR Newswire (US)Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
11/05/202307h00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
11/05/202307h00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
26/04/202308h00PR Newswire (US)Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023NASDAQ:PHARPharming Group NV
19/04/202308h00PR Newswire (US)Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023NASDAQ:PHARPharming Group NV
19/04/202307h36PR Newswire (US)Notice of First Quarter 2023 ResultsNASDAQ:PHARPharming Group NV
13/04/202313h11PR Newswire (US)Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023NASDAQ:PHARPharming Group NV
11/04/202314h58Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
11/04/202307h00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
 Showing the most relevant articles for your search:NASDAQ:PHAR

Kürzlich von Ihnen besucht

Delayed Upgrade Clock